Navigoe Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Navigoe Wealth Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$0	Buy	+1	New	+$302	﹤0.01%	435

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Navigoe Wealth Management's ALNY Position: Q2 2026 in Review

Navigoe Wealth Management opened a new position in Alnylam Pharmaceuticals (ALNY) in Q2 2026: 1 share worth $0. The stake represents ﹤0.01% of the portfolio and ranks #435 among its holdings.

784 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Navigoe Wealth Management held 1 share of Alnylam Pharmaceuticals worth $0 as of Q2 2026.
Alnylam Pharmaceuticals was a new Navigoe Wealth Management position in Q2 2026.
Alnylam Pharmaceuticals made up ﹤0.01% of Navigoe Wealth Management's portfolio in Q2 2026, its #435 holding.
784 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Navigoe Wealth Management's 13F filing for Q2 2026, filed 31 Jul 2026.